How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story

What happened: Eli Lilly reported exploratory Phase 3b data from the TOGETHER-PsO trial showing Taltz combined with Zepbound altered more immune and metabolic biomarkers than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight, with broader responses as early as Week 12. Key numbers: Broader Why it matters: The data strengthens the idea that Lilly's cardiometabolic and immunology assets can work together, but does not materially change near term focus on obesity and diabetes volumes or the risk around GLP 1 pricing pressure and litigation exposure. Market: -2.6% by next close ($54.00 on Oct 14), -31.0% YTD

Eli Lilly reported exploratory Phase 3b data from the TOGETHER-PsO trial showing Taltz combined with Zepbound altered more immune and metabolic biomarkers than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight, with broader responses as early as Week 12.

The data strengthens the idea that Lilly's cardiometabolic and immunology assets can work together, but does not materially change near term focus on obesity and diabetes volumes or the risk around GLP 1 pricing pressure and litigation exposure. Market: -2.6% by next close ($54.00 on Oct 14), -31.0% YTD